Marcus H. Snow, MD

What are your thoughts on the recent launch of Renflexis in the United States?

I think that it will be very interesting to see what happens now that we have 3 versions of infliximab on the market. Will this drive the cost down? I think that it remains to be seen. I think, as you look at what has happened since the first biosimilar for infliximab has hit the market, you have seen insurance companies—United, for example, actually signed a contract with Remicade to stay with the bio-originator. I think you are going to see some of this, but I think it will be interesting to see the uptake and how this happens, and I think we will start to see the outcomes of this moving forward.

Videos

Marcus H. Snow, MD, Assistant Professor Rheumatology, University of Nebraska, discusses the recent launch of a new biosimilar infliximab, Renflexis, in the United States. 

Dr Marcus H. Snow: The US Launch of Renflexis

Are there special considerations when using biosimilars in children?

Generally, no. Ultimately, in the pediatric realm, we end up having a lot of extrapolation of data and the biosimilars with the pediatric population should not be; ideally, this would be studied as much as it is in the adult world, but we just do not have that as often.

Marcus H. Snow, MD, Assistant Professor of Rheumatology, University of Nebraska, discusses the use of biosimilar treatments in children. 

Marcus H. Snow, MD

Dr Marcus H. Snow: The US Launch of Renflexis

Dr Marcus H. Snow: Biosimilar Treatments in Children